Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID S STOKESBERRY

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1427032234
CMS profile
19736
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,843.60

97 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,833.12 96
Education $10.48 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID S STOKESBERRY

NPI 1427032234 · CMS profile ID 19736

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427032234?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID S STOKESBERRY, NPI 1427032234, CMS profile ID 19736. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427032234?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID S STOKESBERRY, NPI 1427032234, CMS profile ID 19736. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427032234?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID S STOKESBERRY, NPI 1427032234, CMS profile ID 19736, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 97 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1427032234?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

97 matching records · $1,843.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 97 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 97.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Madrigal Pharmaceuticals $23.4912/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248313912 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.7312/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223846632 CMS
ABBVIE INC. $24.0312/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419454 CMS
ABBVIE INC. $19.6812/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419450 CMS
ABBVIE INC. $17.6212/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419445 CMS
Medtronic, Inc. $56.3111/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218874964 CMS
ABBVIE INC. $31.4611/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419441 CMS
ABBVIE INC. $20.1711/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419437 CMS
ABBVIE INC. $8.9911/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419431 CMS
GENZYME CORPORATION $15.1011/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233636970 CMS
Regeneron Healthcare Solutions, Inc. $24.0811/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213051819 CMS
Janssen Biotech, Inc. $10.2210/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174434525 CMS
Celltrion USA Inc. $24.5810/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250832909 CMS
Novo Nordisk Inc $21.8410/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188297326 CMS
ABBVIE INC. $18.9410/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419427 CMS
Gilead Sciences, Inc. $14.4610/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234575006 CMS
Enterra Medical, Inc. $80.0010/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253281412 CMS
ABBVIE INC. $22.1910/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419424 CMS
Celltrion USA Inc. $19.6410/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250832907 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.7210/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223879683 CMS
ABBVIE INC. $19.2810/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419420 CMS
Janssen Biotech, Inc. $13.0110/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174446298 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.2610/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223876330 CMS
Janssen Scientific Affairs, LLC $23.5310/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174188226 CMS
Phathom Pharmaceuticals, Inc. $11.6310/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219243362 CMS
ABBVIE INC. $9.8709/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419416 CMS
Madrigal Pharmaceuticals $25.4509/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248313910 CMS
Gilead Sciences, Inc. $14.0209/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234577349 CMS
Medtronic, Inc. $51.7509/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218874966 CMS
ABBVIE INC. $12.6809/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419412 CMS
ABBVIE INC. $10.9009/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419408 CMS
ABBVIE INC. $24.2909/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419404 CMS
GENZYME CORPORATION $21.6809/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233636922 CMS
ABBVIE INC. $21.3609/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419399 CMS
Gilead Sciences, Inc. $17.5509/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234553037 CMS
ABBVIE INC. $5.8309/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419394 CMS
ABBVIE INC. $24.1509/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419391 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.1709/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223867444 CMS
Ardelyx, Inc. $18.0609/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247886264 CMS
ABBVIE INC. $13.2308/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419387 CMS
ABBVIE INC. $6.0808/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419384 CMS
Lilly USA, LLC $26.8408/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186561040 CMS
ABBVIE INC. $16.7908/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419380 CMS
ABBVIE INC. $12.3308/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419376 CMS
Ipsen Biopharmaceuticals, Inc $17.9608/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208825941 CMS
Janssen Biotech, Inc. $9.5408/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174432620 CMS
ABBVIE INC. $16.7408/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419372 CMS
Amgen Inc. $21.7908/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228593975 CMS
Amgen Inc. $21.8008/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228593977 CMS
ABBVIE INC. $14.3508/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419368 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $51.29 5
PY2020 $197.03 5
PY2021 $249.67 10
PY2022 $93.99 7
PY2024 $99.26 5
PY2025 $1,843.60 97

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $108,902.60 28
PY2024 Principal investigator $94,981.85 42
PY2023 Principal investigator $412,886.37 49
PY2022 Principal investigator $102,314.36 32
PY2021 Principal investigator $163,880.82 41
PY2020 Principal investigator $333,675.73 83
PY2019 Recipient $39,889.86 5
PY2019 Principal investigator $462,244.42 78

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

83 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie, Inc. $1,825.00 12/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-431 No dispute reported 06/30/2026 647606535
Principal investigator 1 AbbVie, Inc. $1,128.90 12/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-000 No dispute reported 06/30/2026 647606575
Principal investigator 1 AbbVie, Inc. $2,160.50 12/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606577
Principal investigator 1 Janssen Research & Development, LLC $13,506.70 12/23/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654247745
Principal investigator 1 AbbVie, Inc. $4,819.35 12/20/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-067 No dispute reported 06/30/2026 647606573
Principal investigator 1 Roche Products Limited $3,044.70 12/10/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681055889
Principal investigator 1 AbbVie, Inc. $1,701.50 12/05/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-234 No dispute reported 06/30/2026 647606537
Principal investigator 1 AbbVie, Inc. $540.45 12/04/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-430 No dispute reported 06/30/2026 647606539
Principal investigator 1 Roche Products Limited $538.20 12/03/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681056465
Principal investigator 1 AbbVie, Inc. $2,436.00 12/02/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M15-991 No dispute reported 06/30/2026 647606579
Principal investigator 1 AbbVie, Inc. $10,265.80 12/02/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606581
Principal investigator 1 AbbVie, Inc. $967.70 12/02/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-000 No dispute reported 06/30/2026 647606583
Principal investigator 1 AbbVie, Inc. $1,545.30 11/29/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-066 No dispute reported 06/30/2026 647606587
Principal investigator 1 AbbVie, Inc. $5,773.75 11/27/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-067 No dispute reported 06/30/2026 647606585
Principal investigator 1 AbbVie, Inc. $8,777.80 11/25/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-431 No dispute reported 06/30/2026 647606541
Principal investigator 1 Janssen Research & Development, LLC $6,702.30 11/18/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654247743
Principal investigator 1 Roche Products Limited $2,690.10 11/05/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681066949
Principal investigator 1 AbbVie, Inc. $13,576.50 11/04/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-675 No dispute reported 06/30/2026 647606543
Principal investigator 1 AbbVie, Inc. $1,536.40 11/04/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-234 No dispute reported 06/30/2026 647606545
Principal investigator 1 AbbVie, Inc. $2,329.50 11/01/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M15-991 No dispute reported 06/30/2026 647606589
Principal investigator 1 AbbVie, Inc. $942.00 10/31/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-431 No dispute reported 06/30/2026 647606533
Principal investigator 1 AbbVie, Inc. $2,096.50 10/31/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606569
Principal investigator 1 AbbVie, Inc. $4,096.40 10/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-067 No dispute reported 06/30/2026 647606563
Principal investigator 1 Janssen Research & Development, LLC $1,389.10 10/07/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654247741
Principal investigator 1 AbbVie, Inc. $1,468.60 10/02/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-066 No dispute reported 06/30/2026 647606565
Principal investigator 1 AbbVie, Inc. $12,717.20 10/02/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M15-991 No dispute reported 06/30/2026 647606567
Principal investigator 1 AbbVie, Inc. $6,662.50 10/01/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-675 No dispute reported 06/30/2026 647606531
Principal investigator 1 AbbVie, Inc. $1,040.50 10/01/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-000 No dispute reported 06/30/2026 647606571
Principal investigator 1 AbbVie, Inc. $476.60 09/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-234 No dispute reported 06/30/2026 647606527
Principal investigator 1 AbbVie, Inc. $3,498.30 09/27/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-431 No dispute reported 06/30/2026 647606529
Principal investigator 1 AbbVie, Inc. $119.60 09/12/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606561
Principal investigator 1 Roche Products Limited $4,635.90 09/12/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681065399
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,172.96 09/10/2019 Non-covered Recipient Entity
Digestive Health Specialists
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk No dispute reported 06/30/2026 686160113
Principal investigator 1 Janssen Research & Development, LLC $4,187.40 09/02/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654247737
Principal investigator 1 AbbVie, Inc. $8,877.80 08/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-431 No dispute reported 06/30/2026 647606523
Principal investigator 1 AbbVie, Inc. $890.40 08/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-067 No dispute reported 06/30/2026 647606557
Principal investigator 1 AbbVie, Inc. $15,468.60 08/29/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-675 No dispute reported 06/30/2026 647606525
Principal investigator 1 AbbVie, Inc. $641.80 08/29/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-066 No dispute reported 06/30/2026 647606555
Principal investigator 1 Roche Products Limited $1,274.40 08/14/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681067295
Principal investigator 1 AbbVie, Inc. $27,122.40 08/08/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-234 No dispute reported 06/30/2026 647606621
Principal investigator 1 AbbVie, Inc. $1,187.40 08/01/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-000 No dispute reported 06/30/2026 647606559
Principal investigator 1 Roche Products Limited $322.00 08/01/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681066945
Principal investigator 1 Roche Products Limited $1,728.00 08/01/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681067309
Principal investigator 1 AbbVie, Inc. $9,457.40 07/31/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-675 No dispute reported 06/30/2026 647606615
Principal investigator 1 AbbVie, Inc. $12,775.15 07/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-067 No dispute reported 06/30/2026 647606553
Principal investigator 1 AbbVie, Inc. $1,136.20 07/29/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-431 No dispute reported 06/30/2026 647606617
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,199.96 07/20/2019 Non-covered Recipient Entity
Digestive Health Specialists
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk No dispute reported 06/30/2026 686160115
Principal investigator 1 Roche Products Limited $40.00 07/19/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681054552
Principal investigator 1 Roche Products Limited $40.00 07/15/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681067301
Principal investigator 1 Roche Products Limited $40.00 07/12/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681056945
Principal investigator 1 Roche Products Limited $40.00 07/12/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681066663
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,339.92 07/09/2019 Non-covered Recipient Entity
Digestive Health Specialists
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk No dispute reported 06/30/2026 686160033
Principal investigator 1 Roche Products Limited $826.20 07/02/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681066961
Principal investigator 1 AbbVie, Inc. $46.00 07/01/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-234 No dispute reported 06/30/2026 647606619
Principal investigator 1 AbbVie, Inc. $1,606.80 06/27/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-431 No dispute reported 06/30/2026 647606611
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,119.06 06/14/2019 Covered Recipient Physician An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk No dispute reported 06/30/2026 686158583
Principal investigator 1 AbbVie, Inc. $11,198.90 06/13/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-675 No dispute reported 06/30/2026 647606613
Principal investigator 1 Celgene Corporation $52.69 06/11/2019 Non-covered Recipient Entity
Digestive Disease Specialists
Ph III Yellowstone CD Maintenance (RPC01-3203) (BMS Study Number: IM047-P16) (RPC01-3203) No dispute reported 06/30/2026 675416939
Principal investigator 1 AbbVie, Inc. $588.50 06/04/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-000 No dispute reported 06/30/2026 647606549
Principal investigator 1 AbbVie, Inc. $7,840.90 06/04/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606551
Recipient Takeda Pharmaceuticals U.S.A., Inc. $9,841.52 05/30/2019 Covered Recipient Physician An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk No dispute reported 06/30/2026 686158587
Principal investigator 1 AbbVie, Inc. $346.80 05/29/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-234 No dispute reported 06/30/2026 647606603
Principal investigator 1 AbbVie, Inc. $18,748.30 05/29/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-234 No dispute reported 06/30/2026 647606605
Principal investigator 1 AbbVie, Inc. $11,646.45 05/29/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-431 No dispute reported 06/30/2026 647606607
Principal investigator 1 AbbVie, Inc. $10,081.30 05/29/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-433 No dispute reported 06/30/2026 647606609
Recipient Takeda Pharmaceuticals U.S.A., Inc. $373.02 05/29/2019 Covered Recipient Physician An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk No dispute reported 06/30/2026 686158591
Principal investigator 1 Roche Products Limited $3,228.30 05/10/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 681064579
Principal investigator 1 Janssen Research & Development, LLC $9,992.70 05/06/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654247735
Principal investigator 1 AbbVie, Inc. $1,763.90 05/02/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606547
Recipient Takeda Pharmaceuticals U.S.A., Inc. $17,595.68 05/02/2019 Covered Recipient Physician An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk No dispute reported 06/30/2026 686158585
Principal investigator 1 Celgene Corporation $15,459.40 04/17/2019 Non-covered Recipient Entity
Digestive Disease Specialists
PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) No dispute reported 06/30/2026 675416935
Recipient Takeda Pharmaceuticals U.S.A., Inc. $10,960.58 04/15/2019 Covered Recipient Physician An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk No dispute reported 06/30/2026 686158589
Principal investigator 1 AbbVie, Inc. $1,713.90 04/04/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606601
Principal investigator 1 Janssen Research & Development, LLC $8,510.00 03/11/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654247733
Principal investigator 1 AbbVie, Inc. $8,976.80 03/01/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606591
Principal investigator 1 Celgene Corporation $21.89 02/19/2019 Non-covered Recipient Entity
Digestive Disease Specialists
PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) No dispute reported 06/30/2026 675416937
Principal investigator 1 Celgene Corporation $29,340.50 02/04/2019 Non-covered Recipient Entity
Digestive Disease Specialists
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) (RPC01-3102) No dispute reported 06/30/2026 675416933
Principal investigator 1 AbbVie, Inc. $1,768.50 01/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606593
Principal investigator 1 AbbVie, Inc. $200.00 01/30/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M15-991 No dispute reported 06/30/2026 647606597
Principal investigator 1 AbbVie, Inc. $1,959.50 01/29/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-431 No dispute reported 06/30/2026 647606599
Principal investigator 1 Celgene Corporation $88.55 01/07/2019 Non-covered Recipient Entity
Digestive Disease Specialists
(RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) (RPC01-3101) No dispute reported 06/30/2026 675416943
Principal investigator 1 AbbVie, Inc. $2,607.80 01/04/2019 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-006 No dispute reported 06/30/2026 647606595
Principal investigator 1 Celgene Corporation $79,678.40 01/02/2019 Non-covered Recipient Entity
Digestive Disease Specialists
(RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) (RPC01-3101) No dispute reported 06/30/2026 675416941